At a hearing in April, Arnold & Porter’s Lisa Blatt implored the U.S. Court of Appeals for the Second Circuit to swiftly overturn an injunction barring Actavis plc from pulling an old version of its blockbuster Alzheimer’s drug, Namenda, off the market. The three-judge panel heeded her plea to act quickly—it ruled less than six weeks after oral arguments—but Blatt’s other arguments apparently weren’t as persuasive.
In a one-page order accompanying a sealed opinion, the panel on Friday decided to keep the injunction in place, affirming a widely reverberating loss for Actavis before U.S. District Judge Robert Sweet in Manhattan.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
